title: Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection.
abstract: There have been reports of relapse after cessation of lamivudine monotherapy for hepatitis B virus (HBV) infection. The aim of this study was to examine factors that predict posttreatment relapse. Comparison 22 patients who experienced relapse with 11 who did not after cessation of therapy showed that predictive factors for nonrelapse were hepatitis B e antigen seroconversion and duration of undetectable HBV DNA load (<0.7 log IU/mL), as determined by HBV real-time detection direct testing. However, 7 of 12 patients with seroconversion experienced relapse after cessation of therapy. Multivariate analysis revealed that the duration of an undetectable HBV DNA load was the only independent predictive factor for nonrelapse (odds ratio, 0.50; 95% confidence interval, 0.27-0.9). More-prolonged lamivudine therapy is required after seroconversion, and persistent duration of an HBV DNA level of <0.7 log IU/mL for >6 months can more accurately aid in the decision of when to stop lamivudine therapy.
authors.affiliation: Department of Gastroenterology, Chukyo Hospital, Nagoya, Japan.
authors.forename: Kiyoaki
authors.initials: K
authors.lastname: Ito
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Etsuro
authors.initials: E
authors.lastname: Orito
authors.forename: Noboru
authors.initials: N
authors.lastname: Hirashima
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Ide
authors.forename: Teruko
authors.initials: T
authors.lastname: Hino
authors.forename: Ryukichi
authors.initials: R
authors.lastname: Kumashiro
authors.forename: Atunaga
authors.initials: A
authors.lastname: Kato
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Nukaya
authors.forename: Kenji
authors.initials: K
authors.lastname: Sakakibara
authors.forename: Motokazu
authors.initials: M
authors.lastname: Mukaide
authors.forename: Hidemi
authors.initials: H
authors.lastname: Ito
authors.forename: Michio
authors.initials: M
authors.lastname: Sata
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Ueda
authors.forename: Masashi
authors.initials: M
authors.lastname: Mizokami
mesh_terms: D000328:Adult; D004279:DNA, Viral / Q000032:analysis / Q000187:drug effects; D005260:Female; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D012008:Recurrence; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D019562:Viral Load
chemical_list: D004279:DNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine